Catalent Doubles Footprint of Oral Solid Dose Facility
Catalent completes a $52 million expansion program for advanced oral solid manufacturing solutions at its Winchester, KY, facility.
Catalent Pharma Solutions, a unit of Catalent, Inc., has announced the April 15 opening of an expansion at its Winchester, KY, manufacturing facility, which doubled the footprint to 180,000 sq. ft. The expansion features newly installed fluid bed capacity, expanded analytical laboratories, and an advanced, open facility design that provides flexibility in supporting the requirements of new customer programs.
The expansion was completed in response to increased customer demand for the manufacture of complex, oral solid formulations, as reported in a company press statement. The Winchester facility has more than 20 years of experience in product development, technology transfer, and commercial manufacturing. The site has produced over 3 billion tablets and capsules annually and launched more than 100 new products into the market since its inception.
Construction work on the expansion began in 2013 with a $35 million facility investment, followed by a subsequent investment in additional fluid bed capacity. The expansion will add as many as 140 new employees at the site, with potential to add further employees.
Source: Catalent Pharma Solutions
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
